Status:
COMPLETED
The Role and Mechanism of TCR-T Cells in Immunotherapy for Acute Myeloid Leukemia
Lead Sponsor:
Shenzhen University General Hospital
Conditions:
Acute Myeloid Leukemia (AML)
Eligibility:
All Genders
18-65 years
Phase:
EARLY_PHASE1
Brief Summary
Acute myeloid leukemia (AML) is the main type of leukemia, accounting for about 60% of all leukemia, with complex pathogenesis and great clinical heterogeneity. Effective targets for AML need to be fu...
Detailed Description
Acute myeloid leukemia (AML) is the main type of leukemia, accounting for about 60% of all leukemia, with complex pathogenesis and great clinical heterogeneity. Effective targets for AML need to be fu...
Eligibility Criteria
Inclusion
- Age 18-65 (≥ 18 years old, ≤ 65 years old)
- gender is not limited
- Acute myeloid leukemia patients
- CR(remission phase, white blood cell count \> 2×10\^9/L after blood picture recovery)
- After 3-4 courses of chemotherapy (the number of courses is not absolute)
- Before the next chemotherapy
Exclusion
- Transformed acute myeloid leukemia
- Secondary acute myeloid leukemia
- Post-transplantation acute myeloid leukemia
- AML-M3
- white blood cell count \<2×10\^9/L
- More than 8 courses of chemotherapy
- Combined with other immune-related diseases
- Pregnancy
Key Trial Info
Start Date :
January 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2020
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06904859
Start Date
January 1 2019
End Date
December 30 2020
Last Update
April 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shenzhen University General Hospital
Shenzhen, Guangdong, China